Search Within

Bone Marrow Transplant

Formats
  1. Meeting Abstract (1531)
  2. Journal Article (1198)
  3. Review (75)
  4. Research Letter (49)
  5. Book Section (34)
  6. Guidelines (26)
  7. Editorial (24)
  8. Correspondence (18)
  9. Conference Paper (14)
  10. Book Whole (1)
  11. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (2971)
  2. Department of Medicine (2971)
  3. Hematologic Malignancies, Division of (2848)
  4. Survivorship Research (1389)
  5. GSK Faculty (931)
  6. CTCR Scholars (874)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (943)
  3. Sean Devlin (470)
  4. Ann Jakubowski (459)
  5. Gunjan Shah (447)
  6. Heather Landau (436)

More People

Years
  1. 2025 (68)
  2. 2024 (212)
  3. 2023 (263)
  4. 2022 (201)
  5. 2021 (177)
  6. 2020 (208)

More Years

Publications
  1. Blood (887)
  2. Biology of Blood and Marrow Transplantation (516)
  3. Bone Marrow Transplantation (175)
  4. Journal of Clinical Oncology (127)
  5. Transplantation and Cellular Therapy (113)
  6. Blood Advances (95)

More Publications

Publishers
  1. American Society of Hematology (989)
  2. Elsevier Inc. (767)
  3. Nature Publishing Group (261)
  4. American Society of Clinical Oncology (130)
  5. Wiley Blackwell (66)
  6. Taylor & Francis Group (65)

More Publishers

Results (2971)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of large B-cell lymphoma (LBCL): Impact of age and specific organ dysfunction
    Meeting Abstract

    Locke, F. L.; Jacobson, C.; Ma, L.; Dong, H.; Hu, Z. H.; Siddiqi, T.; Ahmed, S.; Ghobad, A.; Miklos, D. B.; Lin, Y.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Primary analysis of ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma
    Meeting Abstract

    Locke, F. L.; Miklos, D. B.; Jacobson, C.; Perales, M. A.; Kersten, M. J.; Oluwole, O. O.; Ghobadi, A.; Rapoport, A. P.; McGuirk, J. P.; Pagel, J. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Real-world efficacy and safety outcomes for patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin's lymphoma (aBNHL) treated with commercial tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry
    Meeting Abstract

    Landsburg, D. J.; Frigault, M. J.; Hu, Z. H.; Jaglowski, S.; Locke, F. L.; Ho, C.; Perales, M. A.; Jacobson, C.; Hill, B. T.; Foley, S. R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy of PBCAR0191, an allogeneic `off-the-shelf' CD19-directed CAR-T for patients with relapsed/refractory (R/R) CD19+ B-ALL
    Meeting Abstract

    Jain, N.; Kantarjian, H.; Solomon, S. R.; He, F.; Sauter, C. S.; Heery, C. R.; List, A. F.; Johnson, M. C.; Lou, Y.; Vainorius, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • TP53 mutations identify high-risk peripheral T-cell lymphoma patients treated with CHOP-based chemotherapy
    Meeting Abstract

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Maccaro, C.; Galasso, N.; Sauter, C. S.; Neuman, R.; Khan, N.; Moskowitz, A. J.; Dogan, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy
    Meeting Abstract

    Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world experience
    Meeting Abstract

    Hultcrantz, M.; Orozco, J.; Peterson, T. J.; Derkach, A.; Hassoun, H.; Korde, N.; Lu, S. X.; Mailankody, S.; Patel, D.; Shah, U. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase II study of ruxolitinib pre-, during- and post-hematopoietic celltransplantation for patients with primary or secondary myelofibrosis
    Meeting Abstract

    Hobbs, G.; Kim, H. T.; Bottoms, A. J. S.; Byrne, M. T.; Schroeder, M. A.; Tamari, R.; Wall, S. A.; Defilipp, Z.; El-Jawahri, A.; McAfee, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Iomab with adoptive cellular therapy (Iomab-ACT): A pilot study of 131-I apamistamab followed by CD19-targeted car T-cell therapy for patients with relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma
    Meeting Abstract

    Geyer, M. B.; Cadzin, B.; Halton, E.; Kane, P.; Senechal, B.; Geoghegan, E. M.; Reddy, V.; Berger, M. S.; Ludwig, D.; Pandit-Taskar, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Racial disparities in access to alternative donor allografts persist in the era of "Donors for all"
    Meeting Abstract

    Fingrut, W.; Politikos, I.; Davis, E.; Chinapen, S.; Naputo, K.; Cho, C.; Giralt, S. A.; Gyurkocza, B.; Jakubowski, A. A.; Papadopoulos, E. B.; more...
    Blood (2021)

    Fulltext@MSK | Save